UMM logo

Transplant Center

Current Clinical Trials

Principal Investigator: Stephen Bartlett, M.D.
Source: Federal Grant
Clinical Trial Description: "Solid Organ Transplantation in HIV Positive Patients"
     
Principal Investigator: Benjamin Philosophe, M.D., Ph.D.
Source: Novartis
Clinical Trial Description: "Predictors of Allograft Outcomes Relating to Optimal Induction and Immunosuppressive Regimens for Populations at High Immunological Risk for Poorer Allograft Outcomes"
     
Principal Investigator: Luis Campos, M.D.
Source: Wyeth
Clinical Trial Description: "A Randomized, Open-Label, Comparative Evaluation of Conversion From Calcineurin Inhibitor Treatment to Sirolimus Treatment Versus Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy"
     
Principal Investigator: Matthew Cooper, M.D.
Source: Novartis
Clinical Trial Description: "A Six-Month, Prospective, Multi Center, Open Label, Parallel, Randomized Study of The Safety, Tolerability and Efficacy of Myfortic (Erl080) With Simulect, Corticosteroids, and Two Different Levels of Tacrolimus in De Novo Renal Transplant Recipients (Cerl080a2409)"
     
Principal Investigator: Matthew Cooper, M.D.
Source: Novartis
Clinical Trial Description: "A 24-Month, Multi-Center, Randomized, Open-Label Non-Inferiority Study of The Efficacy and Safety Comparing Two Concentration-Controlled Certican Regimens with Reduced Neoral Versus Myfortic with Standard Dose Neoral in De Novo Renal Transplant Recipients"
     
Principal Investigator: Matthew Cooper, M.D.
Source: Novartis
Clinical Trial Description: "A 4-Week, Multi Center, Double-Blind, Randomized, Parallel Group Study to Compare the Gastrointestinal (GI) Safety and Tolerability of Myfortic and Cellcept when Administered in Combination with Calcineurin Inhibitors (CNI) in Renal Transplant Recipients Experiencing Gastrointestinal Intolerance"
     
Principal Investigator: Stephen Bartlett, M.D., Kristi Silver, M.D.
Source:  
Clinical Trial Description: "Human Islet Transplantation in Non-Uremic Type 1 Diabetic Patients with Normal Native Renal Function"
     
Principal Investigator: Matthew Cooper, M.D.
Source:  
Clinical Trial Description: "Living Donation and Laparoscopic Nephrectomy"
     
Principal Investigator: Stephen Bartlett, M.D.
Source: Department of Defense/Naval Grant
Clinical Trial Description: "A Study of the Safety and Efficacy of the Use of Islet Cell Transplantation in Patients with Type 1 Diabetes"
     
Principal Investigator: Matthew Cooper, M.D.
Source:  
Clinical Trial Description: "Blood-Type Incompatible Live Donor Kidney Transplantation"

 

Projects in Planning

Principal Investigator: Matthew Cooper, M.D.
Source: Pfizer
Clinical Trial Description: "A phase 2 Randomized, Multicenter, Active Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Coadministration of CP-690,550 and Mycophenolate Mofetil/Mycophenolate Sodium in De Novo Kidney Allograft Recipients"
     
Principal Investigator: Rolf Barth, M.D., Matthew Cooper, M.D.
Source: Alavita
Clinical Trial Description: "A Phase 2 Randomized, Double – Blind, Placebo-Controlled Trial to Evalute the Safety and Efficacy Diannexin for the Prevention of Ischemia-Reperfusion Injury in De Novo Kidney Transplant Recipients of Expanded Criteria Donors"
     
Principal Investigator: Matthew Cooper, M.D.
Source: Pfizer
Clinical Trial Description: "Phase 2 Randomized, Multicenter, Active Comparitor-Controlled Trial to Evaluate the Safety and Efficacy of Coadministration of a JAK-3 inhibitor and Mycophenolate Mofetil in De Novo Kidney Allograft Recipients"

This page was last updated on: March 12, 2008.

If you would like to make an appointment or talk to someone about our services, please call 410-328-5408 or 1-800-492-5538.